Summary of Alpha Cognition Conference Call - October 08, 2025 Company Overview - **Company**: Alpha Cognition (NasdaqCM: ACOG) - **Lead Product**: Zunvil, approved by the FDA for mild to moderate Alzheimer's disease in Q3 2024 [2][3] Industry Context - **Target Market**: Long-term care facilities, specifically nursing homes, which represent a $2 billion opportunity for Zunvil [13][14] - **Alzheimer's Disease**: Affects memory, cognitive function, and behavior; approximately 40% of Alzheimer's patients spend their lifespan in assisted living or long-term care [4][14] Core Product Insights - **Zunvil Characteristics**: - A prodrug of galantamine, designed to minimize gastrointestinal side effects [5][6] - Demonstrates improved tolerability with less than 2% of patients reporting GI issues [11] - 0% incidence of insomnia compared to 30% for leading competitors [12] - Proven cognitive effects and functional performance, targeting behavioral symptoms common in Alzheimer's patients [12][13] Commercialization Strategy - **Launch Details**: - Launched in April 2025, generating over 1,500 prescriptions in the first quarter [3][19] - Focused on long-term care market due to high concentration of Alzheimer's patients and fewer payer restrictions [13][14] - **Sales Strategy**: - 50 salespeople targeting nursing homes and medical directors [16] - Engaged with nearly 2,000 nursing homes, with 15% writing prescriptions for Zunvil [17] - Plans for strategic partnerships with pharmacies and long-term care facilities [18] Financial Outlook - **Revenue**: Generated approximately $1.7 million in the first quarter, with expectations for steady growth [19] - **Expense Guidance**: Projected expenses between $34 to $38 million, targeting profitability by 2027 [3][20] - **Market Potential**: If Zunvil captures 10% to 25% of the market, it could generate $200 to $600 million in sales [20][31] Pipeline and Future Developments - **Additional Products**: - A sublingual formulation for patients with swallowing difficulties, expected to enter clinical studies in early 2026 [21] - A product targeting cognitive impairment from concussions, with data expected mid-next year [22] - **Market Expansion**: Plans to enter the neurology segment, representing a $1.5 billion opportunity, post achieving break-even status [25][26] Competitive Landscape - **Market Size**: The acetylcholinesterase inhibitor market is estimated at $6 to $7 billion, with historical products achieving billion-dollar sales [29][30] - **Differentiation**: Zunvil's unique formulation and tolerability profile position it as a disruptive force in the market [33] Key Takeaways - **Management Team**: Experienced team with a strong track record in drug launches [24] - **Future Focus**: Continued education for healthcare providers and strategic partnerships to enhance market penetration [33] This summary encapsulates the key points discussed during the Alpha Cognition conference call, highlighting the company's strategic direction, product differentiation, and market potential.